Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Global Forecast 2024-2030

Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Global Forecast 2024-2030

The Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 1.50 billion in 2023 and expected to reach USD 1.88 billion in 2024, at a CAGR 25.34% to reach USD 7.32 billion by 2030.

The market of viral vector and plasmid DNA manufacturing encompasses the production of plasmid DNA and viral vectors used for gene delivery to develop gene therapies and genetically modified organisms. Viral vectors are tools that molecular biologists use to produce genetic material in cells. This procedure can be completed inside a living organism (in vivo) or cell culture (ex vivo). Meanwhile, plasmid DNA is a small circular DNA strand that can be used to transfer genetic material similarly. Applications for these products range significantly and include clinical gene therapy for hereditary diseases, genetic vaccines, and cancer treatment strategies. End-users of viral vector and plasmid DNA products include pharmaceutical and biopharmaceutical companies, academic and research institutions, and clinical research organizations. The evolution of the viral vector and plasmid DNA manufacturing market is influenced by the increasing number of gene therapy candidates entering clinical trials, advancement in molecular biology technologies, rising investment in personalized medicine, and the growing prevalence of targeted diseases. The commitment of regulatory agencies to fast-track approvals for emerging therapies also supports market expansion. However, the market faces certain challenges, such as the high manufacturing cost due to complex production methods, regulatory hurdles, concerns regarding the safety and efficacy of gene therapy products, and the need for highly specialized technical expertise. On the other hand, the latest potential opportunities in the market include developments in vector design to reduce immunogenicity, increases in scale-up production processes to meet market demands, and advancements in gene-editing tools such as CRISPR/Cas9. Emerging economies expanding their biotechnological sectors also present significant opportunities for market players.

Regional Insights

The Americas, particularly the United States, remain at the forefront of biopharmaceutical research, including developing and manufacturing viral vectors and plasmid DNA. Recent investments and initiatives, such as launching advanced therapy production facilities and federal funding for gene therapy manufacturing, underscore the region's capacity in this field. Canada also contributes significantly, with its collaborative approach between academia and industry facilitating advanced research and development in this sector. The EU countries have been proactive in fostering a conducive environment for the growth of advanced therapy medicinal products (ATMPs), which include gene therapies employing viral vectors and plasmid DNA. Customer purchasing behavior in Europe is often influenced by the alignment of product offerings to these regulatory incentives and the established healthcare systems supporting innovative treatments. The Middle East, while still developing in this field, is seeing increased interest and investment in biotechnology, leading to a gradual increase in regional capabilities for manufacturing viral vectors and plasmid DNA. On the other hand, Africa presents a diverse picture, with South Africa heading in research capabilities, albeit on a smaller scale than global leaders. In APAC, China's commitment to biotech innovation is evident in its growing presence in the viral vector and plasmid DNA manufacturing landscape, supported by substantial government investments in research infrastructure and favorable policies for biotech companies. The country's fast-growing biotech sector translates to strong consumer demand and aggressive customer purchasing behavior towards local and international partnerships and technologies. India, while an emerging player in this field, is experiencing burgeoning demand due to its large population and increasing focus on healthcare innovation.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Viral Vector & Plasmid DNA Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing number of gene therapy clinical trials worldwide
• Growing advancement in molecular biology technologies

Market Restraints

• High cost of manufacturing of viral vector & plasmid DNA solutions

Market Opportunities

• Growing introduction of novel viral vector & plasmid DNA solutions
• Rising investment in personalized medicine

Market Challenges

• Concerns regarding the safety and efficacy of gene therapy products

Market Segmentation Analysis

• Cell Line: Growing usage of in-vitro cell lines in controlled laboratory environments
• Type: Increasing need for plasmid DNA manufacturing to deliver genetic material into cells
• Transfection: Rising popularity of stable transfection for gene therapy and drug development
• End User: Expanding the potential of viral vectors & plasmid DNA across pharmaceutical & biopharmaceutical companies for the development and production of next-generation vaccines

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Viral Vector & Plasmid DNA Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Viral Vector & Plasmid DNA Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Ajinomoto Co., Inc. to Acquire Forge Biologics for USD 620 Million

Ajinomoto Co., Inc. acquired Forge Biologics, valued at USD 620 million. This strategic move signals Ajinomoto Co.'s expansion into the gene therapy sector in line with its ASV Initiatives 2030 Roadmap, positioning the acquisition as a key growth driver in its Healthcare portfolio.

Genezen Secures USD 18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities

Genezen, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, secured an additional USD 18.5 million in growth equity investment, spearheaded by Ampersand Capital Partners. This strategic financial boost will propel Genezen's expansion in producing retroviral, lentiviral, and adeno-associated viral (AAV) vectors, enhancing its ability to execute a growing portfolio of customer projects.

CCRM Partners with Membio to Streamline Production of Viral Vectors for Cell and Gene Therapies

CCRM has partnered with Membio Inc. to tackle the challenges of viral vector production, a critical and costly bottleneck in the industry. This collaboration explore combining Membio’s bioreactor system with CCRM’s virus-producing cell line.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Viral Vector & Plasmid DNA Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., Akron Biotech, Avid Bioservices, Inc., Batavia Biosciences B.V., BioNTech IMFS GmbH, Biovian Oy, c-LEcta GmbH, Charles River Laboratories International, Inc., Creative Biogene, FILTROX AG, Forge Biologics By Ajinomoto Co., Inc., FUJIFILM Diosynth Biotechnologies Inc., GE HealthCare Technologies, Inc., GeneOne Life Science, Inc., Genezen, Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PerkinElmer Inc., REGENXBIO Inc., Spark Therapeutics, Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., and Wuxi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
• Plasmid DNA
• Viral Vector
• Adeno-Associated Virus
• Adenovirus
• Lentivirus
• Cell Line
• In-vitro
• In-Vivo
• Transfection
• Stable Transfection
• Transient Transfection
• Indication
• Cancer
• Genetic Disorder
• Infectious Disease
• Workflow
• Downstream Processing
• Fill-finish
• Purification
• Upstream Processing
• Vector Amplification & Expansion
• Vector Recovery/Harvesting
• Application
• Cell Therapy
• Gene Therapy
• Vaccinology
• End User
• Pharmaceutical & Biopharmaceutical Companies
• Research Institutes
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year